Simplification of combination antiretroviral therapy (cART) and the brain—a real-life experience
- 22 Downloads
Modern antiretroviral combination therapy (cART) has transformed HIV from a life-threatening infection into a chronic disease. However, the life-long treatment has side effects that frequently have a negative impact on patients’ quality of life. Thus, there are some efforts to “simplify” therapy, i.e. apply regimens with three or fewer antiretroviral substances. However, neurologists are relatively sceptical towards this cART “simplification”, because the capacity of simplified regimens to access the cerebrospinal fluid (CSF) might be too weak to effectively suppress viral load in this compartment. Thus, data of a big Neuro-AIDS cohort of 4992 HIV-positive patients consecutively recruited over three decades were retrospectively analysed in terms of neurocognitive performance of patients switched to simplified therapy regimens. To test whether simplified drug regimens result in new neuropsychological deficits or the worsening of pre-existing ones in HIV+ patients. Three groups of HIV+ patients were switched from triple therapy to three different two drug regimens (n = 177 to lamivudine/PI, n = 37 to INI/PI, and n = 303 to dual PI); three other groups of patients put from one to an alternative triple combination (n = 290 ABC/3TC/PI, n = 244 TDF/FTC/PI, and n = 158 TDF/FTC/NNRTI) for whatever reason served as controls. All patients were followed up over 4 years maximum. Every patient group improved immunologically and virologically after the switch. However, patients who switched to INI/PI combinations remained stable in neuropsychological tests, while a considerable percentage of patients who switched to other treatments demonstrated a decline. Remarkably, a high percentage of the patients switched to “simplified drug regimens” was not well-controlled virologically before the switch. HIV-positive patients with simplified therapy regimens show some benefit in terms of systemic infection surrogate markers (CD4 ± cell count and plasma viral load); however, neurocognitive deficits do not improve, but remain stable in most cases.
KeywordsHIV infection Antiretroviral combination therapy Two drug regimens
HIV-associated neurocognitive disorder
less drug regimen
boosted protease inhibitors
nucleoside inhibitors of the reverse transcriptase
non-nucleoside inhibitors of the reverse transcriptase
simplified drug regimens
strategic timing of antiretroviral therapy
The authors thank all patients giving their informed consent to publish their data and all doctors presenting their patients in our out-patient department.
Gabriele Arendt wrote the manuscript; Svenja Schlonies collected the data; Eser Orhan helped in data evaluation and statistics; Olaf Stüve helped in writing the manuscript and did the language editing; all authors: manuscript revision.
The study was kindly supported by Janssen-Cilag GmbH, Germany.
Compliance with ethical standards
Conflicts of interest
Gabriele Arendt received financial support from Janssen-Cilag GmbH, Germany and from ViiV Healthcare and honoraria for lectures and consultancies from Abbvie, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag GmbH, Germany and MSD. All the other authors declare that they have no conflict of interest.
- Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders (HAND). Neurology 69(18):1789–1799CrossRefGoogle Scholar
- Arribas JR, Pialoux G, Gathe J, di Perri G, Reynes J, Tebas P, Nguyen T, Ebrahimi R, White K, Piontkowsky D (2014) Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis 14(7):581–589CrossRefGoogle Scholar
- Arribas JR, Girard PM, OLE/RIS-EST13 Study Group et al (2015) Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis 15:85–792CrossRefGoogle Scholar
- Borghetti A, Baldin G, Lombardi F, Ciccullo A, Capetti A, Rusconi S, Sterrantino G, Latini A, Cossu MV, Gagliardini R, de Luca A, di Giambenedetto S (2018) Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication. HIV Med 19:452–454. https://doi.org/10.1111/hiv.12611 CrossRefGoogle Scholar
- Calcagno A, Montrucchio C, Capetti A, Guaraldi G, Cenderello G, Calza L, Lanzafame M, Marinaro L, Tettoni MC, Trentini L, D'Avolio A, di Perri G, Bonora S (2016) Raltegravir plus nevirapine as maintenance antiretroviral therapy in HIV-positive patients: safety, Efficacy and Pharmacokinetics. Curr HIV Res 14(1):54–60CrossRefGoogle Scholar
- Calza L, Cafaggi M, Colangeli V, Borderi M, Barchi E, Lanzafame M, Nicole’ S, Degli Antoni AM, Bon I, Re MC, Viale P (2018) Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy. Infect Dis (Lond) 50(5):352–360CrossRefGoogle Scholar
- Capetti AF, Cossu MV, Orofino G, Sterrantino G, Cenderello G, de Socio GV, Cattelan AM, Soria A, Rusconi S, Riccardi N, Baldin GM, Niero FP, Barbarini G, Rizzardini G (2017) A dual regimen of ritonavir/darunavir plus dolutegravirfor rescue or simplification of rescue therapy: 48 weeks’observational data. BMC Infect Dis 17(1):658CrossRefGoogle Scholar
- Fabbiani M, di Giambenedetto S, Quiros-Roldan E, Latini A, Vullo V, Antinori A, Castagna A, Orofino G, Francisci D, Grilli E, Madeddu G, Grima P, Rusconi S, del Pin B, Mondi A, Borghetti A, Focà E, Colafigli M, de Luca A, Cauda R (2014) Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial. J Int AIDS Soc 17:19808CrossRefGoogle Scholar
- Gantner P, Koeppel C, Partisani M, Batard ML, Bernard-Henry C, Cheneau C, de Mautort E, Priester M, Muret P, Sueur C, Fafi-Kremer S, Rey D (2014) Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study. Scan J Infect Dis 46(12):838–845CrossRefGoogle Scholar
- Imaz A, Niubó J, Amara A, Khoo S, Ferrer E, Tiraboschi JM, Acerete L, Garcia B, Vila A, Podzamczer D (2018) Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39). J Neurovirol 24:391–397. https://doi.org/10.1007/s13365-018-0626-4 CrossRefPubMedGoogle Scholar
- Klove H (1963) Clinical neuropsychology. In: Foster FM (ed) The medical clinics of North America. Saunders, New YorkGoogle Scholar
- Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur J, McCutchan J, Morgello S, Simpson D, Grant I, Ellis RJ, CHARTER Group (2008) Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65(1):65–70CrossRefGoogle Scholar
- Letendre SL, FitzSimons C et al (2010). Correlates of CSF viral loads in 1221 volunteers of the CHARTER cohort. 17th Conference on Retroviruses and opportunistic Infections (CROI) Montreal. Abstrno: 172Google Scholar
- Maggiolo F, Di Filippo E et al (2016) NRTI sparing therapy in virologically controlled HIV-1 infected subjects: Results of a Controlled, Randomized Trail (Probe). J Acquir Immune Defic Syndr 72(1):46–51Google Scholar
- Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J, Pérez I, Gatell JM, SPIRAL Study Group (2010) Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 24(11):1697–1707CrossRefGoogle Scholar
- Martínez-Rebollar M, Muñoz A, Pérez I, Hidalgo S, Brunet M, Laguno M, González A, Calvo M, Loncà M, Blanco JL, Martínez E, Gatell JM, Mallolas J (2013) Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and darunavir/ritonavir 800/100 mg once daily in HIV-1-infected patients. Ther Drug Monit 35(4):552–556CrossRefGoogle Scholar
- Mondi A, Fabbiani M, Ciccarelli N, Colafigli M, D'Avino A, Borghetti A, Gagliardini R, Cauda R, de Luca A, di Giambenedetto S (2015) Efficacy and safety of treatment simplification to atazanavir/ritonavir+lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the ATLAS pilot study. J Antimicrob Chemother 70:1843–1849CrossRefGoogle Scholar
- Osih RB, Taffé P, Rickenbach M, Gayet-Ageron A, Elzi L, Fux C, Opravil M, Bernasconi E, Schmid P, Günthard HF, Cavassini M, Swiss HIV Cohort Study (2010) Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study. AIDS Res Hum Retrovir 26(11):1239–1246CrossRefGoogle Scholar
- Perez-Molina JA, Rubio R et al (2015) GESIDA 7011 Study Group. Dual treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infect Dis 15:775–784CrossRefGoogle Scholar
- Power C, Selnes OA et al (1985) HIV dementia scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol 18(9):1611–1616Google Scholar
- Pozniak A, Markowitz M, Mills A, Stellbrink HJ, Antela A, Domingo P, Girard PM, Henry K, Nguyen T, Piontkowsky D, Garner W, White K, Guyer B (2014) Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis 14(7):590–599CrossRefGoogle Scholar
- Reitan RM, Wolfson D (1985) The Halstead-Reitan. Neuropsychological Test Battery, Neuropsychological Press, TuconGoogle Scholar
- Smith A (1982) Symbol Digit Modalities Test (SDMT). Manual (revised). Western Psychological Services, Los AngelesGoogle Scholar
- Spreen O, Strauss E (2001) Controlled word association. A compendium of neuropsychological tests New York 2001. Oxford University Press, pp 221–229Google Scholar